BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2411 related articles for article (PubMed ID: 25789199)

  • 1. Erratum: The future of high-grade glioma: Where we are and where are we going: Erratum.
    Surg Neurol Int; 2015; 6():37. PubMed ID: 25789199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corrigendum.
    Paediatr Child Health; 2015; 20(8):466-7. PubMed ID: 26744561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erratum: An Erratum to Correct Typographical Errors.
    Ann Rehabil Med; 2016 Dec; 40(6):1151. PubMed ID: 28119849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erratum: An Erratum to Correct Typographical Errors.
    Ann Rehabil Med; 2016 Oct; 40(5):959. PubMed ID: 27847729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erratum: Effect of granatin B on the glioma cancer by inducing apoptosis.
    Jin Z; Yu Y; Jin RH; Wang YB; Xu HY
    Am J Transl Res; 2017; 9(2):802. PubMed ID: 28337308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erratum: ERRATUM.
    Urol Ann; 2011 May; 3(2):61. PubMed ID: 21747592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erratum: ERRATUM.
    Indian J Anaesth; 2011 Mar; 55(2):121. PubMed ID: 21712866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erratum: MicroRNA-217 inhibits cell proliferation and invasion by targeting Runx2 in human glioma.
    Zhu Y; Zhao H; Feng L; Xu S
    Am J Transl Res; 2021; 13(11):13216-13218. PubMed ID: 34956543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erratum: MicroRNA-181 inhibits the proliferation, drug sensitivity and invasion of human glioma cells by targeting Selenoprotein K (SELK).
    Xu CH; Xiao LM; Zeng EM; Chen LK; Zheng SY; Li DH; Liu Y
    Am J Transl Res; 2021; 13(8):9914-9917. PubMed ID: 34540128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erratum: β-elemene promotes the senescence of glioma cells through regulating YAP-CDK6 signaling.
    Yang D; Xu X; Wang X; Feng W; Shen X; Zhang J; Liu H; Xie C; Wu Q; Miao X; Guo Y; Cai H; Wu L; Zhou S; Yao X; Wang Y; Xie T; Huang Z
    Am J Cancer Res; 2024; 14(2):931-933. PubMed ID: 38455421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erratum to: Conference materials. 15
    Cent Eur J Immunol; 2016; 41(4):442. PubMed ID: 28559744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erratum: Dehydrocostus lactone, a natural sesquiterpene lactone, suppresses the biological characteristics of glioma, through inhibition of the NF-κB/COX-2 signaling pathway by targeting IKKβ.
    Wang J; Yu Z; Wang C; Tian X; Huo X; Wang Y; Sun C; Feng L; Ma J; Zhang B; Yang Q; Ma X; Xu Y
    Am J Cancer Res; 2021; 11(3):1009-1011. PubMed ID: 33791170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erratum to "LRIG1 Enhances Chemosensitivity by Modulating BCL-2 Expression and Receptor Tyrosine Kinase Signaling in Glioma Cells" by Guo Z, et al. (Yonsei Med J 2014;55:1196-205.).
    Yonsei Med J; 2014 Nov; 55(6):1748. PubMed ID: 25492572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erratum: Author Corrections.
    Obstet Gynecol Sci; 2018 Sep; 61(5):645. PubMed ID: 30255004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erratum: Addendum of Informed Consent Statements.
    Endocrinology and Metabolism Editorial Office
    Endocrinol Metab (Seoul); 2018 Mar; 33(1):137. PubMed ID: 29589396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erratum.
    Can J Respir Ther; 2015; 51(3):72. PubMed ID: 26283873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erratum.
    Chin J Cancer Res; 2015 Apr; 27(2):E1. PubMed ID: 25937785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erratum.
    Song BC; Cho YK; Jwa H; Choi EK; Kim HU; Song HJ; Na SY; Boo SJ; Jeong SU
    Clin Mol Hepatol; 2015 Mar; 21(1):104. PubMed ID: 25834809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erratum: Achilles' heel of triple negative cancer.
    Ocaña A; Montero JC; Pandiella A
    Oncoscience; 2015; 2(7):659. PubMed ID: 26328268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erratum: Natural borneol is a novel chemosensitizer that enhances temozolomide-induced anticancer efficiency against human glioma by triggering mitochondrial dysfunction and reactive oxide species-mediated oxidative damage [Corrigendum].
    Onco Targets Ther; 2018; 11():8273-8274. PubMed ID: 30538496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 121.